Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: email@example.com. Type 508 Accommodation in the subject line of e-mail.
Postexposure Prophylaxis of Persons with Discrete Identifiable Exposures
to Hepatitis B Virus (HBV)
This appendix provides recommendations for management of persons who are exposed to HBV through a
discrete, identifiable exposure to blood or body fluids that contain blood. Recommendations for management of infants born
to mothers who test positive for hepatitis B surface antigen (HBsAg) are provided in this report (see
Prevention of Perinatal HBV Transmission and Management of Pregnant Women).
Unvaccinated persons (Table C-1) or persons known not to have
responded to a complete hepatitis B vaccine series
should receive both hepatitis B immune globulin (HBIG) and hepatitis B vaccine as soon as possible after exposure
(preferably <24 hours). For sexual exposures, HBIG should not be
administered more than 14 days after exposure. Hepatitis
B vaccine may be administered simultaneously with HBIG in a separate injection site. The hepatitis B vaccine series
should be completed using the age-appropriate vaccine dose and schedule (see
Tables 2 and
Persons who are in the process of being vaccinated but who have not completed the vaccine series should receive
the appropriate dose of HBIG and should complete the vaccine series.
Children and adolescents who have written documentation of a complete hepatitis B vaccine series and who did
not receive postvaccination testing should receive a single vaccine booster dose.
Source with Unknown HBsAg Status
Unvaccinated persons (Table C-1) should receive the hepatitis B vaccine series with the first dose initiated as soon
as possible after exposure, preferably <24 hours. The vaccine series should be completed using the age-appropriate dose
and schedule (see Tables 2,
3, and 5).
Persons who are not fully vaccinated should complete the vaccine series.
Children and adolescents with written documentation of a complete hepatitis B vaccine series require no
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
All MMWR HTML versions of articles are electronic conversions from ASCII text
into HTML. This conversion may have resulted in character translation or format errors in the HTML version.
Users should not rely on this HTML document, but are referred to the electronic PDF version and/or
the original MMWR paper copy for the official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents,
U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800.
Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to